Dobre Daniela, van Veldhuisen Dirk J, Goulder Michael A, Krum Henry, Willenheimer Ronnie
Department of Clinical Pharmacology, University Medical Centre Groningen, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands.
Cardiovasc Drugs Ther. 2008 Oct;22(5):399-405. doi: 10.1007/s10557-008-6116-9. Epub 2008 Jun 5.
To assess the clinical effects and safety profile of initial monotherapy with either bisoprolol or enalapril in elderly patients with heart failure (HF).
In CIBIS III, 1010 patients with mild to moderate HF and age>or=65 years were randomized to monotherapy with either bisoprolol or enalapril for 6 months.
Bisoprolol had a similar effect as enalapril on the combined end-point of all-cause mortality or hospitalization (HR 1.02; p=0.90), as well as on each of the individual end-points. A trend towards fewer sudden deaths was observed with bisoprolol (NS). On the other hand, more cases of worsening HF requiring hospitalization or occurring while in hospital were observed in the bisoprolol group (HR 1.67; p=0.03). The two groups were similar with regard to treatment cessations and early introduction of the second drug.
Bisoprolol and enalapril had a similar effect on the combined end-point of mortality or hospitalization during 6 months monotherapy. However, more worsening HF events were observed in the bisoprolol group.
评估比索洛尔或依那普利初始单药治疗老年心力衰竭（HF）患者的临床疗效和安全性。
在CIBIS III研究中，1010例年龄≥65岁的轻至中度HF患者被随机分为比索洛尔或依那普利单药治疗组，为期6个月。
比索洛尔在全因死亡率或住院的联合终点方面与依那普利效果相似（风险比1.02；p = 0.90），在各个单独终点方面也是如此。观察到比索洛尔组猝死病例有减少趋势（无统计学意义）。另一方面，比索洛尔组观察到更多需要住院或住院期间发生的HF恶化病例（风险比1.67；p = 0.03）。两组在治疗中断和早期加用第二种药物方面相似。
在6个月的单药治疗中，比索洛尔和依那普利在死亡率或住院的联合终点方面效果相似。然而，比索洛尔组观察到更多HF恶化事件。
